1. 1379PDImpact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study. (23rd October 2018) Authors: Dziadziuszko, R; Mok, T S; Camidge, D R; Shaw, A T; Noe, J; Nowicka, M; Liu, T; Mitry, E; Peters, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evidence of improving survival of patients with rectal cancer in France: a population based study. Issue 3 (1st March 1999) Authors: Finn-Faivre, C; Maurel, J; Benhamiche, A M; Herbert, C; Mitry, E; Launoy, G; Faivre, J Journal: Gut Issue: Volume 44:Issue 3(1999) Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC. (23rd October 2018) Authors: Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; Yang, L; Wang, C; Morcos, P N; Mitry, E; Liu, T; Zhang, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC). (25th November 2018) Authors: Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; Yang, L; Wang, C; Morcos, P N; Mitry, E; Li, Z Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗